Overview

Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

Status:
Not yet recruiting

Trial end date:
2032-12-31

Target enrollment:

Participant gender:

Summary

Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to Isatuximab for the treatment of patients with newly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) as maintenance after SCT.

Phase:

Phase 2

Details

Lead Sponsor:

Karolinska Institutet

Collaborator:

Sanofi